Cyprotex's gADME offers personalised dosing opportunities
This article was originally published in Scrip
Executive Summary
Preclinical ADME-Tox services company, Cyprotex, has launched a Genomic ADME service (gADME) with the potential to reduce the number of drugs being discarded in early development and create personalised dose regimens.